Pasar al contenido principal

MECANISMOS RESPONSABLES DEL FENOTIPO PATOLOGICO EN ENFERMEDADES NEUROMETABOLICAS RARAS Y APROXIMACIONES TERAPEUTICAS PERSONALIZADAS

PID2019-105344RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cardiomyocytes Derived from Induced Pluripotent Stem Cells as a Disease Model for Propionic Acidemia

  • Alonso-Barroso, Esmeralda
  • Pérez, Belén
  • Ruiz Desviat, Lourdes
  • Richard, Eva
© 2021 by the authors, Propionic acidemia (PA), one of the most frequent life-threatening organic acidemias, is caused by mutations in either the PCCA or PCCB genes encoding both subunits of the mitochondrial propionyl-CoA carboxylase (PCC) enzyme. Cardiac alterations (hypertrophy, dilated cardiomyopathy, long QT) are one of the major causes of mortality in patients surviving the neonatal period. To overcome limitations of current cellular models of PA, we generated induced pluripotent stem cells (iPSCs) from a PA patient with defects in the PCCA gene, and successfully differentiated them into cardiomyocytes. PCCA iPSC-derived cardiomyocytes exhibited reduced oxygen consumption, an accumulation of residual bodies and lipid droplets, and increased ribosomal biogenesis. Furthermore, we found increased protein levels of HERP, GRP78, GRP75, SIG-1R and MFN2, suggesting endoplasmic reticulum stress and calcium perturbations in these cells. We also analyzed a series of heart-enriched miRNAs previously found deregulated in the heart tissue of a PA murine model and confirmed their altered expression. Our novel results show that PA iPSC-cardiomyocytes represent a promising model for investigating the pathological mechanisms underlying PA cardiomyopathies, also serving as an ex vivo platform for therapeutic evaluation., Research reported in this work was funded by Grant PAF107 from the Propionic Acidemia Foundation; SAF2016-76004-R from Spanish Ministry of Economy, Industry and Competitiveness— Agencia Estatal de Investigación and European Regional Development Fund (Fondos Feder); PID2019- 105344RB-I00/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and by LCF/PR/PR16/11110018 from Fundación Isabel Gemio, Fundación La Caixa., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RNA solutions to treat inborn errors of metabolism

  • Martínez-Pizarro, Ainhoa
  • Desviat, Lourdes R.
RNA-based therapies are a new, rapidly growing class of drugs that until a few years ago were being used mainly in research in rare diseases. However, the clinical efficacy of recently approved oligonucleotide drugs and the massive success of COVID-19 RNA vaccines has boosted the interest in this type of molecules of both scientists and industry, as wells as of the lay public. RNA drugs are easy to design and cost effective, with greatly improved pharmacokinetic properties thanks to progress in oligonucleotide chemistry over the years. Depending on the type of strategy employed, RNA therapies offer the versatility to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. Currently, there are more than a dozen RNA-based drugs approved for clinical use, including some for specific inborn errors of metabolism (IEM), and many other in different stages of development. New initiatives in n-of-1 RNA drug development offer new hope for patients with rare diseases and/or ultra-rare mutations. RNA-based therapeutics include antisense oligonucleotides, aptamers, small interfering RNAs, small activating RNAs, microRNAs, lncRNAs and messenger RNAs. Further research and collaborations in the fields of chemistry, biology and medicine will help to overcome major challenges in their delivery to target tissues. Herein, we review the mechanism of action of the different therapeutic approaches using RNA drugs, focusing on those approved or in clinical trials to treat IEM., This work was funded by grant PID2019-105344RB-I00/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and COST (European Cooperation in Science and Technology) Action CA17103. Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dysregulated Cell Homeostasis and miRNAs in Human iPSC-Derived Cardiomyocytes from a Propionic Acidemia Patient with Cardiomyopathy

  • Álvarez, Mar
  • Ruiz-Sala, Pedro
  • Pérez, Belén
  • Ruiz Desviat, Lourdes
  • Richard, Eva
Propionic acidemia (PA) disorder shows major involvement of the heart, among other alterations. A significant number of PA patients develop cardiac complications, and available evidence suggests that this cardiac dysfunction is driven mainly by the accumulation of toxic metabolites. To contribute to the elucidation of the mechanistic basis underlying this dysfunction, we have successfully generated cardiomyocytes through the differentiation of induced pluripotent stem cells (iPSCs) from a PCCB patient and its isogenic control. In this human cellular model, we aimed to examine microRNAs (miRNAs) profiles and analyze several cellular pathways to determine miRNAs activity patterns associated with PA cardiac phenotypes. We have identified a series of upregulated cardiac-enriched miRNAs and alterations in some of their regulated signaling pathways, including an increase in the expression of cardiac damage markers and cardiac channels, an increase in oxidative stress, a decrease in mitochondrial respiration and autophagy; and lipid accumulation. Our findings indicate that miRNA activity patterns from PA iPSC-derived cardiomyocytes are biologically informative and advance the understanding of the molecular mechanisms of this rare disease, providing a basis for identifying new therapeutic targets for intervention strategies., This research was funded by Grants PAF107 and PAF113 from the Propionic Acidemia Foundation; PID2019-105344RB-I00/AEI/10.13039/501100011033 from the Spanish Ministry of Science and Innovation and European Regional Development Fund (Fondos Feder); and by a Grant from Fundación Ramón Areces (XX National Call 2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional analysis of novel variants identified in cis in the PCCB gene in a patient with propionic acidemia

  • Martínez-Pizarro, Ainhoa
  • Calmels, Nadège
  • Schalk, Audrey
  • Wicker, Camille
  • Richard, Eva
  • Desviat, Lourdes R.
Next-generation sequencing has improved the diagnosis of inborn errors of metabolism, allowing rapid confirmation of cases detected by clinical/biochemical studies or newborn screening. The challenge, however, remains for establishing the pathogenicity of the identified variants, especially for novel missense changes or small in-frame deletions. In this work we report a propionic acidemia patient exhibiting a severe neonatal form with coma and hyperammonaemia. Genetic analysis identified the previously described pathogenic PCCB variant p.R512C in the maternal allele and two novel PCCB variants in cis in the paternal allele, p.G246del and p.S322F. Expression analysis in a eukaryotic system confirmed the deleterious effect of the novel missense variant and of the one amino acid deletion, as they both exhibited reduced protein levels and reduced or null PCC activity compared to the wild-type construct. Accordingly, the double mutant resulted in no residual activity. This study increases the knowledge of the genotype-phenotype correlations in the rare disease propionic acidemia and highlights the necessity of functional analysis of novel variants to understand their contribution to disease severity and to accurately classify their pathogenic status. In conclusion, two novel PCCB pathogenic variants have been identified, expanding the current mutational spectrum of propionic acidemia., This work was funded by Spanish Ministry of Science and Innovation and European Regional Development Fund (grants PID2019-105344RB-I00/AEI/10.13039/501100011033 and PID2022-137238OB-I00) and by Fundación Ramón Areces (grant from XX National Call 2020). Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulating PCCA gene expression by modulation of pseudoexon splicing patterns to rescue enzyme activity in propionic acidemia

  • Spangsberg Petersen, Ulrika Simone
  • Dembic, Maja
  • Martínez-Pizarro, Ainhoa
  • Richard, Eva
  • Lolle Holm, Lise
  • Foged Havelund, Jesper
  • Koed Doktor, Thomas
  • Røssel Larsen, Martin
  • Færgeman, Nils J.
  • Desviat, Lourdes R.
  • Storstein Andresen, Brage
Pseudoexons are nonfunctional intronic sequences that can be activated by deep-intronic sequence variation. Activation increases pseudoexon inclusion in mRNA and interferes with normal gene expression. The PCCA c.1285-1416A>G variation activates a pseudoexon and causes the severe metabolic disorder propionic acidemia by deficiency of the propionyl-CoA carboxylase enzyme encoded by PCCA and PCCB. We characterized this pathogenic pseudoexon activation event in detail and identified hnRNP A1 to be important for normal repression. The PCCA c.1285-1416A>G variation disrupts an hnRNP A1-binding splicing silencer and simultaneously creates a splicing enhancer. We demonstrate that blocking this region of regulation with splice-switching antisense oligonucleotides restores normal splicing and rescues enzyme activity in patient fibroblasts and in a cellular model created by CRISPR gene editing. Interestingly, the PCCA pseudoexon offers an unexploited potential to upregulate gene expression because healthy tissues show relatively high inclusion levels. By blocking inclusion of the nonactivated wild-type pseudoexon, we can increase both PCCA and PCCB protein levels, which increases the activity of the heterododecameric enzyme. Surprisingly, we can increase enzyme activity from residual levels in not only patient fibroblasts harboring PCCA missense variants but also those harboring PCCB missense variants. This is a potential treatment strategy for propionic acidemia., This work was supported by grants to B.S.A. from the Danish Medical Research Council (no. 9039-00281B) and the Novo Nordisk Foundation (NNF 19OC0058588), and by grants to L.R.D.: Grant PID2019-105344RB-I00/AEI/10.13039/501100011033 from the Spanish Ministry of Science and Innovation and the European Regional Development Fund, and grant XX National Call 2020 from Fundación Ramón Areces. The work was performed in Odense, Denmark, and in Madrid, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene

  • Martínez-Pizarro, Ainhoa
  • Leal, Fátima
  • Lolle Holm, Lise
  • Doktor, Thomas K
  • Petersen, Ulrika S. S.
  • Bueno, María
  • Thöny, Beat
  • Pérez, Belén
  • Andresen, Brage S.
  • Desviat, Lourdes R.
We report two new 6-pyruvoyl-tetrahydropterin synthase splicing variants identified through genomic sequencing and transcript analysis in a patient with tetrahydrobiopterin deficiency, presenting with hyperphenylalaninemia and monoamine neurotransmitter deficiency. Variant c.243 + 3A>G causes exon 4 skipping. The deep-intronic c.164-672C>T variant creates a potential 5′ splice site that leads to the inclusion of four overlapping pseudoexons, corresponding to exonizations of an antisense short interspersed nuclear element AluSq repeat sequence. Two of the identified pseudoexons have been reported previously, activated by different deep-intronic variants, and were also detected at residual levels in control cells. Interestingly, the predominant pseudoexon is nearly identical to a disease causing activated pseudoexon in the F8 gene, with the same 3′ and 5′ splice sites. Splice switching antisense oligonucleotides (SSOs) were designed to hybridize with splice sites and/or predicted binding sites for regulatory splice factors. Different SSOs corrected the aberrant pseudoexon inclusion, both in minigenes and in fibroblasts from patients carrying the new variant c.164-672C>T or the previously described c.164-716A>T. With SSO treatment PTPS protein was recovered, illustrating the therapeutic potential of the approach, for patients with different pseudoexon activating variants in the region. In addition, the natural presence of pseudoexons in the wild type context suggests the possibility of applying the antisense strategy in patients with hypomorphic PTS variants with the purpose of upregulating their expression to increase overall protein and activity., This work was funded by grant PID2019-105344RB-I00/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation, COST (European Cooperation in Science and Technology) Action CA17103, Fundación Isabel Gemio, Fundación La Caixa (LCF/PR/PR16/11110018) and grants to B.S.A. from the Danish Medical Research Council (FSS) (No. 9039-00281B) and the Novo Nordisk Foundation (NNF19OC0058588). Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PAH deficient pathology in humanized c.1066-11G>A phenylketonuria mice

  • Martínez-Pizarro, Ainhoa
  • Picó, Sara
  • López-Márquez, Arístides
  • Rodríguez-López, Claudia
  • Montalvo, Elena
  • Álvarez, Mar
  • Castro, Margarita
  • Ramón-Maiques, Santiago
  • Pérez, Belén
  • Lucas, José J.
  • Richard, Eva
  • Desviat, Lourdes R.
16 páginas, 8 figuras, We have generated using CRISPR/Cas9 technology a partially humanized mouse model of the neurometabolic disease phenylketonuria (PKU), carrying the highly prevalent PAH variant c.1066-11G>A. This variant creates an alternative 3' splice site, leading to the inclusion of 9 nucleotides coding for 3 extra amino acids between Q355 and Y356 of the protein. Homozygous Pah c.1066-11A mice, with a partially humanized intron 10 sequence with the variant, accurately recapitulate the splicing defect and present almost undetectable hepatic PAH activity. They exhibit fur hypopigmentation, lower brain and body weight and reduced survival. Blood and brain phenylalanine levels are elevated, along with decreased tyrosine, tryptophan and monoamine neurotransmitter levels. They present behavioral deficits, mainly hypoactivity and diminished social interaction, locomotor deficiencies and an abnormal hind-limb clasping reflex. Changes in the morphology of glial cells, increased GFAP and Iba1 staining signals and decreased myelinization are observed. Hepatic tissue exhibits nearly absent PAH protein, reduced levels of chaperones DNAJC12 and HSP70 and increased autophagy markers LAMP1 and LC3BII, suggesting possible coaggregation of mutant PAH with chaperones and subsequent autophagy processing. This PKU mouse model with a prevalent human variant represents a useful tool for pathophysiology research and for novel therapies development., This work was funded by Spanish Ministry of Science Innovation and Universities MICIU/AEI and European Regional Development Fund (grants PID2019-105344RB-I00/AEI/10.13039/501100011033 and PID PID2022-137238OB-I00/AEI/10.13039/501100011033), by Fundación Ramón Areces (XX National Call 2020) and from TaNeDS Europe 2017 (Daichii Sankyo) research grant. Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis

  • Soria, Leandro R.
  • Makris, Georgios
  • D’Alessio, Alfonso M.
  • De Angelis, Angela
  • Boffa, Iolanda
  • Pravata, Veronica M.
  • Rüfenacht, Véronique
  • Attanasio, Sergio
  • Nusco, Edoardo
  • Arena, Paola
  • Ferenbach, Andrew T.
  • Paris, Debora
  • Cuomo, Paola
  • Motta, Andrea
  • Nitzahn, Matthew
  • Lipshutz, Gerald S.
  • Martínez-Pizarro, Ainhoa
  • Richard, Eva
  • Desviat, Lourdes R.
  • Häberle, Johannes
  • van Aalten, Daan M. F.
  • Brunetti-Pierri, Nicola
Life-threatening hyperammonemia occurs in both inherited and acquired liver diseases affecting ureagenesis, the main pathway for detoxification of neurotoxic ammonia in mammals. Protein O-GlcNAcylation is a reversible and nutrient-sensitive post-translational modification using as substrate UDP-GlcNAc, the end-product of hexosamine biosynthesis pathway. Here we show that increased liver UDP-GlcNAc during hyperammonemia increases protein O-GlcNAcylation and enhances ureagenesis. Mechanistically, O-GlcNAcylation on specific threonine residues increased the catalytic efficiency for ammonia of carbamoyl phosphate synthetase 1 (CPS1), the rate-limiting enzyme in ureagenesis. Pharmacological inhibition of O-GlcNAcase, the enzyme removing O-GlcNAc from proteins, resulted in clinically relevant reductions of systemic ammonia in both genetic (hypomorphic mouse model of propionic acidemia) and acquired (thioacetamide-induced acute liver failure) mouse models of liver diseases. In conclusion, by fine-tuned control of ammonia entry into ureagenesis, hepatic O-GlcNAcylation of CPS1 increases ammonia detoxification and is a novel target for therapy of hyperammonemia in both genetic and acquired diseases., This work was supported by grants of Fondazione Telethon Italy (to N.B.‐P.), MIUR (PRIN2017 to N.B.‐P.), of the Swiss National Science Foundation (grant 320030_176088 to J.H.), of the US National Institutes of Health grants (R21NS091654 and R01NS100979 both to G.S.L.), of the Spanish Ministry of Science and Innovation (PID2019-105344RB-I00/AEI/10.13039/501100011033 to L.R.D. and E.R.), and by a Wellcome Trust Investigator Award (110061 to D.M.F.v.A.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Renal phenotyping in a hypomorphic murine model of propionic aciduria reveals common pathomechanisms in organic acidurias

  • Schumann, Anke
  • Martinez-Pizarro, Ainhoa
  • Richard, Eva
  • Schell, Christoph
  • Kössinger, Anna Laura
  • Zeyer, Karina A.
  • Tholen, Stefan
  • Schilling, Oliver
  • Barry, Michael
  • Neubauer, Björn
  • Köttgen, Michael
  • Hannibal, Luciana
  • Desviat, Lourdes R.
  • Spiekerkötter, Ute
Mutations in the mitochondrial enzyme propionyl-CoA carboxylase (PCC) cause propionic aciduria (PA). Chronic kidney disease (CKD) is a known long-term complication. However, good metabolic control and standard therapy fail to prevent CKD. The pathophysiological mechanisms of CKD are unclear. We investigated the renal phenotype of a hypomorphic murine PA model (Pcca(A138T)) to identify CKD-driving mechanisms. Pcca(A138T) mice show elevated retention parameters and express markers of kidney damage progressing with time. Morphological assessment of the Pcca(A138T) mouse kidneys indicated partial flattening of tubular epithelial cells and focal tubular-cystic dilation. We observed altered renal mitochondrial ultrastructure and mechanisms acting against oxidative stress were active. LC–MS/MS analysis confirmed disease-specific metabolic signatures and revealed disturbances in mitochondrial energy generation via the TCA cycle. Our investigations revealed altered mitochondrial networks shifted towards fission and a marked reduction of mitophagy. We observed a steep reduction of PGC-1-α, the key mediator modulating mitochondrial functions and a counter actor of mitochondrial fission. Our results suggest that impairment of mitochondrial homeostasis and quality control are involved in CKD development in PA. Therapeutic targeting of the identified pathways might help to ameliorate CKD in addition to the current treatment strategies., This study was supported by the Division of Inborn Errors of Metabolism at the Department of Pediatrics, Adolescent Medicine and Neonatology Freiburg and by the Freiburg Center for Rare Diseases. AS and MK were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 431984000—CRC 1453 Nephrogenetics. AS was supported by the Research Commission of the Faculty of Medicine at the University of Freiburg (SCHU2175/21) and by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. MK was supported by Germany’s Excellence Strategy (CIBSS, EXC-2189, project ID 390939984). KAZ was supported by the Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg. The Proteomic Platform—Core Facility was supported by the Medical Faculty of the University of Freiburg to O.S. (2021/A3-Sch). The Translational Metabolomics Core Facility was supported by the Faculty of Medicine, University Hospital Freiburg to LH and US. (Grant Nr. 2023/A7-Han). The research performed in Madrid was funded by Spanish Ministry of Science and Innovation and European Regional Development Fund (Grants PID2019-105344RB-I00/AEI/https://doi.org/10.13039/501100011033 and PID2022-137238OB-I00) and by Fundación Ramón Areces (grant from XX National Call 2020). Open Access funding enabled and organized by Projekt DEAL.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology

  • Fulgencio-Covián, Alejandro
  • Álvarez, Mar
  • Pepers, Barry A.
  • López-Márquez, Arístides
  • Ugarte, Magdalena
  • Pérez, Belén
  • van Roon-Mom, Willeke M.C.
  • Desviat, Lourdes R.
  • Richard, Eva
Propionic acidemia (PA) is an inherited metabolic disease caused by mutations in the PCCA and PCCB genes. We have previously generated an induced pluripotent stem cell (iPSC) line (UAMi004-A) from a PA patient with the c.1218_1231del14ins12 (p.Gly407Argfs*14) homozygous mutation in the PCCB gene. Here, we report the generation of the isogenic control in which the mutation was genetically corrected using CRISPR/Cas9 technology. Off-target editing presence was excluded and the iPSCs had typical embryonic stem cell-like morphology and normal karyotype that expressed pluripotency markers and maintained their in vitro differentiation potential., Research reported in this work was funded by Grant PAF107 from the Propionic Acidemia Foundation and by grants SAF2016-76004-R from Spanish Ministry of Economy, Industry and Competitiveness - Agencia Estatal de Investigación and European Regional Development Fund (Fondos Feder) and PID2019-105344RB-I00/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation. The authors thank Federación Española de Enfermedades Metabólicas Hereditarias and the patients’ families for their collaboration and for agreeing to participate in the study, the Cytogenetic unit from Centro Nacional de Investigaciones Oncológicas (CNIO) and Elena Montalvo for their excellent technical assistance. Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces. AFC is a PhD student funded by the FPI-UAM program.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology

  • Fulgencio-Covián, Alejandro
  • Álvarez, Mar
  • Pepers, Barry A.
  • López-Márquez, Arístides
  • Ugarte, Magdalena
  • Pérez, Belén
  • van Roon-Mom, Willeke M.C.
  • Desviat, Lourdes R.
  • Richard, Eva
Propionic acidemia (PA) is an inherited metabolic disease caused by mutations in the PCCA and PCCB genes. We have previously generated an induced pluripotent stem cell (iPSC) line (UAMi004-A) from a PA patient with the c.1218_1231del14ins12 (p.Gly407Argfs*14) homozygous mutation in the PCCB gene. Here, we report the generation of the isogenic control in which the mutation was genetically corrected using CRISPR/Cas9 technology. Off-target editing presence was excluded and the iPSCs had typical embryonic stem cell-like morphology and normal karyotype that expressed pluripotency markers and maintained their in vitro differentiation potential., Research reported in this work was funded by Grant PAF107 from the Propionic Acidemia Foundation and by grants SAF2016-76004-R from Spanish Ministry of Economy, Industry and Competitiveness - Agencia Estatal de Investigación and European Regional Development Fund (Fondos Feder) and PID2019-105344RB-I00/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation. The authors thank Federación Española de Enfermedades Metabólicas Hereditarias and the patients’ families for their collaboration and for agreeing to participate in the study, the Cytogenetic unit from Centro Nacional de Investigaciones Oncológicas (CNIO) and Elena Montalvo for their excellent technical assistance. Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces. AFC is a PhD student funded by the FPI-UAM program.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cardiac Complications of Propionic and Other Inherited Organic Acidemias

  • Park,Kyung Chan
  • Krywawych,Steve
  • Richard,Eva
  • Desviat,Lourdes R.
  • Swietach,Pawel
Clinical observations and experimental studies have determined that systemic acid-base disturbances can profoundly affect the heart. A wealth of information is available on the effects of altered pH on cardiac function but, by comparison, much less is known about the actions of the organic anions that accumulate alongside H ions in acidosis. In the blood and other body fluids, these organic chemical species can collectively reach concentrations of several millimolar in severe metabolic acidoses, as in the case of inherited organic acidemias, and exert powerful biological actions on the heart that are not intuitive to predict. Indeed, cardiac pathologies, such as cardiomyopathy and arrhythmia, are frequently reported in organic acidemia patients, but the underlying pathophysiological mechanisms are not well established. Research efforts in the area of organic anion physiology have increased dramatically in recent years, particularly for propionate, which accumulates in propionic acidemia, one of the commonest organic acidemias characterized by a high incidence of cardiac disease. This Review provides a comprehensive historical overview of all known organic acidemias that feature cardiac complications and a state-of-the-art overview of the cardiac sequelae observed in propionic acidemia. The article identifies the most promising candidates for molecular mechanisms that become aberrantly engaged by propionate anions (and its metabolites), and discusses how these may result in cardiac derangements in propionic acidemia. Key clinical and experimental findings are considered in the context of potential therapies in the near future., This work was supported by a British Heart Foundation 4-Year Non-Clinical Ph.D. Studentship to KP (FS/16/59/32735), by Great Ormond Street Hospital NHS Foundation Trust (SK), a Propionic Acidemia Foundation grant to ER (PAF107), a Spanish Ministry of Science and Innovation grant to LD and ER (PID2019-105344RB-I00/AEI/10.13039/501100011033), and by Corpus Christi College (University of Oxford) and a British Heart Foundation Programme Grant to PS (RG/15/9/31534).